MadhavanV.PillaiMD

Oncology • Boise, ID

Professor, Medical Oncology, Jefferson Medical College-Thos Jefferson Univ

Join to view full profile

Dr. Pillai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Pillai's full profile

Already have an account?

Office
1055 N Curtis Rd
Boise, ID 83706
Phone+1 208-367-2121

Fax+1 208-367-3966
Is this information wrong?

Education & Training

Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 1979 - 1982
University of Kerala Medical CollegeClass of 1966

Certifications & Licensure

PA State Medical License 2010 - 2024
TX State Medical License 2014 - 2024
ID State Medical License 2016 - 2020
VA State Medical License 1980 - 2014
DC State Medical License 1989 - 2002
MD State Medical License 1991 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Start of enrollment: 2012 Sep 01
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

2 citations
Gastrointestinal Stromal Tumors: A Review.
Aakanksha Asija, Alex V. Mejia, Anthony Prestipino, Madhavan V. Pillai> ;American Journal of Therapeutics. 2016 Mar 1
A phase I open-label, dose-escalation study of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Littman SJ, Monti D, Newberg A, Bazzan A, Pillai MV, Lewis N, Yeo C, Levine M, Mitchell EP> ;J. Clin. Oncol.. 2012-02-01
28 citations
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary ana...
Edith P. Mitchell, Bilal Piperdi, Mario E. Lacouture, Heather Shearer, Nicholas Iannotti, Madhavan V. Pillai, Feng Xu, M. Yassine> ;Clinical Colorectal Cancer. 2011 Dec 1
48 citations
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgras...
J. Randolph Hecht, Madhavan V. Pillai, Russell Gollard, William Heim, Forrest Swan, Ravi Patel, Lyndah Dreiling, May Mo, Imtiaz Malik> ;Clinical Colorectal Cancer. 2010 Apr 1
324 citations
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on S...
Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi, Madhavan V. Pillai, Heather Shearer, Nicholas Iannotti, Feng Xu, M. Yassine> ;Journal of Clinical Oncology. 2010 Mar 10
Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal c...
Mitchell EP, Lacouture M, Shearer H, Iannotti N, Piperdi B, Pillai M, Xu F, Yassine M> ;J. Clin. Oncol.. 2009-06-20
Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study.
Hecht JR, Pillai M, Gollard R, Dreiling L, Mo M, Malik I> ;J. Clin. Oncol.. 2009-05-20
Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal c...
Mitchell EP, Lacouture M, Shearer H, Iannotti N, Piperdi B, Pillai M, Xu F, Yassine M> ;J. Clin. Oncol.. 2009-05-20
A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or i...
Mitchell EP, LaCouture ME, Shearer H, Iannotti N, Piperdi B, Pillai MV, Xu F, Couture M, Yassine M> ;J. Clin. Oncol.. 2008-05-20
Join now to see all

Hospital Affiliations

Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Doctor's Hospital at RenaissanceEdinburg, Texas